Table 1.
Study descriptions for RNA-seq dataset.
| Study | Clinicaltrials.gov registration | Cancer type | Treatment setting | Patient numbera | Patient characteristics | Treatment |
|---|---|---|---|---|---|---|
| KEYNOTE-001 | NCT01295827 | Melanoma | Second- or later-line treatment of ipilimumab-refractory advanced melanoma | 83 | Median (range) age: 62 (23–94) years; 59% male; ECOG 0/1: 70%/30%; PD-L1 positive: 73% | Pembrolizumab 2 mg/kg or 10 mg/kg Q2W, or 10 mg/kg Q3W |
| KEYNOTE-006 | NCT01866319 | Melanoma | First- or later-line treatment of unresectable stage III or metastatic melanoma; up to 1 previous systemic therapy | 393 | Median (range) age: 62 (18–88) years; 62% male; ECOG 0/1: 69%/31%; PD-L1 positive: 86% | Pembrolizumab 10 mg/kg Q3W or 10 mg/kg Q2W |
| KEYNOTE-052 | NCT02335424 | Urothelial carcinoma | First-line treatment for cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer | 186 | Median (range) age: 73 (34–91) years; 77% male; ECOG 0/1: 23%/76%; PD-L1 positive: 82% | Pembrolizumab 200 mg Q3W |
| KEYNOTE-012 | NCT01848834 | Head and neck squamous cell carcinoma | First- or later-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck | 88 | Median (range) age: 61 (25–83) years; 80% male; ECOG 0/1: 27%/73%; PD-L1 positive: 91%; Cohort B2: 72%, Cohort B: 28% | Pembrolizumab 10 mg/kg Q2W or 200 mg Q3W |
| KEYNOTE-055 | NCT02255097 | Head and neck squamous cell carcinoma | Second- or later-line treatment of platinum- and cetuximab-refractory head and neck cancer | 59 | Human papillomavirus–negative | Pembrolizumab 200 mg Q3W |
| Median (range) age: 61 (33–83) years; 75% male; ECOG 0/1: 14%/86%; PD-L1 positive: 86% | ||||||
| KEYNOTE-086 | NCT02447003 | Triple-negative breast cancer | First and later-line treatment for metastatic triple-negative breast cancer | 132 | All women | Pembrolizumab 200 mg Q3W |
| Median (range) age: 52 (26–82) years; ECOG 0/1: 58%/42%; Cohort A: 70%, Cohort B: 30%; PD-L1 positive: 75% | ||||||
| KEYNOTE-059 | NCT02335411 | Gastric or gastroesophageal junction cancer | First- or later-line treatment for patients with untreated recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma | 92 | Median (range) age: 64 (24–89) years; 73% male; ECOG 0/1: 40%/60%; Cohort 1: 100%; PD-L1 positive: 62% | Pembrolizumab 200 mg Q3W |
| KEYNOTE-427 | NCT02853344 | Clear cell renal cell carcinoma | First-line treatment for patients with locally advanced or metastatic renal cell carcinoma | 78 | Cohort A | Pembrolizumab 200 mg Q3W |
| Median (range) age: 65 (39–87) years; 77% male; IMDC: Favorable, 37%; Intermediate, 51%; Poor, 12%; PD-L1 positive: 46% | ||||||
| KEYNOTE-100 | NCT02674061 | Ovarian cancer | First- or later-line treatment of recurrent ovarian cancer | 77 | Cohort A | Pembrolizumab 200 mg Q3W |
| Median (range) age: 62 (34–89) years; all women; ECOG 0/1: 69%/31% |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic RCC Database Consortium; PD-L1, programmed death ligand 1; Q2W, every 2 weeks; Q3W, every 3 weeks.
aIncluding only patients receiving pembrolizumab monotherapy and for whom RNA-seq data were available.